Medivation (NASDAQ:MDVN) During the most recent session, the shares traded at 0.23 points or 0.39% higher at $59.7. The money flow data is unimpressive with the net money flow value of $(-0.57) million. As per the intraday data, the upticks measured $0.47 million and the downticks measured $1.04 million. As a result, the up/down ratio registered a value of 0.45. The shares have seen 0.62% price change for the week.A block trade also made an entry with $0 million flowing in through upticks while $0.68 million flew out through downticks. The block tradeoff had the up/down ratio of 0. The net money flow for this big transaction was $(-0.68) million.
The stock has recorded a 20-day Moving Average of 2.18% and the 50-Day Moving Average is 2.19%. The company shares have rallied 2.48% in the past 52 Weeks. On May 10, 2016 The shares registered one year high of $62.94 and one year low was seen on February 9, 2016 at $26.41. The 50-day moving average is $60.34 and the 200 day moving average is recorded at $45.72. S&P 500 has rallied 1.93% during the last 52-weeks.
Medivation (NASDAQ:MDVN): The stock opened at $59.35 on Tuesday but the bulls could not build on the opening and the stock topped out at $59.83 for the day. The stock traded down to $58.61 during the day, due to lack of any buying support eventually closed down at $58.97 with a loss of -0.84% for the day. The stock had closed at $59.47 on the previous day. The total traded volume was 2,215,293 shares.
Currently the company Insiders own 4% of Medivation shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -18.41% . Institutional Investors own 90.82% of Medivation shares. During last six month period, the net percent change held by insiders has seen a change of 0.7%. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Powell Andrew Kenneth William, officer (SVP, General Counsel & Crp Sec) of Medivation, Inc., had unloaded 2,578 shares at an average price of $60.42 in a transaction dated on June 6, 2016. The total value of the transaction was worth $155,763.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.